ReviewVaccines2020
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.Journal of the American Academy of Dermatology · 2021Guideline
- The Global Burden and Temporal Trends of Psoriasis, 1990-2021: Implications From the COVID-19 Pandemic.Health science reports · 2026Article
- Evaluating the Association Between Systemic Treatments for Moderate to Severe Psoriasis and SARS-CoV-2 Infection Outcomes.Journal of psoriasis and psoriatic arthritis · 2025Article
- Outcomes of SARS-CoV-2 infection in patients under treatment with pharmacological immunosuppression. A Swiss cohort study.Archives of medical science : AMS · 2025Article
- Development and trends in metabolomics studies in psoriasis: A bibliometric analysis of related research from 2011 to 2024.Heliyon · 2024Article
- The IMPACT of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany.Dermatology and therapy · 2023Article
- Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry.Dermatology and therapy · 2023Article
- Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?International journal of molecular sciences · 2022Review
- Association of psoriasis with risk of COVID-19: A 2-sample Mendelian randomization study.Journal of the American Academy of Dermatology · 2022Article
- Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.Dermatologic therapy · 2022Observational
- Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.Journal of clinical medicine · 2022Review
- Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review.Vaccines · 2022Review
- Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.Biomedicines · 2022Review
- Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience.Dermatologic therapy · 2022Article
- Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?Frontiers in medicine · 2022Article
- Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course.Journal of cosmetic dermatology · 2021Article
- COVID-19 illness and autoimmune diseases: recent insights.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- Article
- Dermatologists' attitude towards psoriasis treatment during the COVID-19 pandemic.Drugs in context · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic plaque psoriasis is an inflammatory skin disease affecting 2-3% of the general population. Approximately one-third of patients are candidates for systemic immunosuppressive treatments, such as synthetic or biological disease-modifying antirheumatic drugs, because of disease extensions, localization in sensitive or visible areas and/or resistance to topical treatments. These therapies have been associated with increased risk of infection, including upper respiratory tract viral infection. Psoriasis is frequently associated with cardio-metabolic comorbidities, such as obesity and diabetes, that are risk factors for poor prognosis in the case of coronavirus disease (COVID-19) pneumonia. A narrative review of the literature based on an electronic search of the PubMed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.